Hemmer B - Search Results

1

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. Among authors: hemmer b. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.

2

New concepts in the immunopathogenesis of multiple sclerosis.

Hemmer B, Archelos JJ, Hartung HP. Hemmer B, et al. Nat Rev Neurosci. 2002 Apr;3(4):291-301. doi: 10.1038/nrn784. Nat Rev Neurosci. 2002. PMID: 11967559 Review. No abstract available.

3

New immunopathologic insights into multiple sclerosis.

Hemmer B, Kieseier B, Cepok S, Hartung HP. Hemmer B, et al. Curr Neurol Neurosci Rep. 2003 May;3(3):246-55. doi: 10.1007/s11910-003-0085-y. Curr Neurol Neurosci Rep. 2003. PMID: 12691630 Free PMC article. Review.

4

Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.

Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Kieseier BC, et al. Among authors: hemmer b. Muscle Nerve. 2004 Aug;30(2):131-56. doi: 10.1002/mus.20076. Muscle Nerve. 2004. PMID: 15266629 Review.

5

[Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis].

Stüve O, Nessler S, Hartung HP, Hemmer B, Wiendl H, Kieseier BC. Stüve O, et al. Among authors: hemmer b. Nervenarzt. 2005 Jun;76(6):701-7. doi: 10.1007/s00115-004-1842-0. Nervenarzt. 2005. PMID: 15580467 Review. German.

6

Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis.

Cepok S, Rosche B, Grummel V, Vogel F, Zhou D, Sayn J, Sommer N, Hartung HP, Hemmer B. Cepok S, et al. Among authors: hemmer b. Brain. 2005 Jul;128(Pt 7):1667-76. doi: 10.1093/brain/awh486. Epub 2005 Mar 30. Brain. 2005. PMID: 15800022

7

Multiple sclerosis--novel insights and new therapeutic strategies.

Kieseier BC, Hemmer B, Hartung HP. Kieseier BC, et al. Among authors: hemmer b. Curr Opin Neurol. 2005 Jun;18(3):211-20. doi: 10.1097/01.wco.0000169735.60922.fb. Curr Opin Neurol. 2005. PMID: 15891402 Review.

8

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.

Hemmer B, Stüve O, Kieseier B, Schellekens H, Hartung HP. Hemmer B, et al. Lancet Neurol. 2005 Jul;4(7):403-12. doi: 10.1016/S1474-4422(05)70117-4. Lancet Neurol. 2005. PMID: 15963443 Review.

9

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.

Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK. Frohman EM, et al. Among authors: hemmer b. Arch Neurol. 2005 Sep;62(9):1345-56. doi: 10.1001/archneur.62.9.1345. Arch Neurol. 2005. PMID: 16157741 Review.

10

Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.

Neuhaus O, Wiendl H, Kieseier BC, Archelos JJ, Hemmer B, Stüve O, Hartung HP. Neuhaus O, et al. Among authors: hemmer b. J Neuroimmunol. 2005 Nov;168(1-2):128-37. doi: 10.1016/j.jneuroim.2005.01.024. J Neuroimmunol. 2005. PMID: 16171875

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

514 results

Search Page